Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER, PR, Her2 Negative) Locally Advanced Non-resectable and/or Metastatic Breast Cancer

NCT00633464 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00633464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00633464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER, PR, Her2 Negative) Locally Advanced Non-resectable and/or Metastatic Breast Cancer
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
May 31, 2011
Enrollment
79 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, triple negative locally advanced non-resectable breast cancer